Integrating touchscreen-based geriatric assessment and frailty screening for adults with acute myelogenous leukemia to drive personalized treatment decisions.

Authors

Debra Wujcik

Debra Wujcik

Carevive, Inc., Nashville, TN

Debra Wujcik , Nikolaos Papadantonakis , Sarah Allison Wall , Margaret T. Kasner , OMER HASSAN JAMY , William Dudley , Stacey A. Ingram , Valerie Lawhon , UI Son , Matthew Dudley

Organizations

Carevive, Inc., Nashville, TN, Emory University, Atlanta, GA, The Ohio State University, Columbus, OH, Thomas Jefferson University, Philadelphia, PA, University of Tennessee, Memphis, TN, Carevive Systems, Inc., Miami, FL, University of Alabama at Birmingham, Birmingham, AL, Ohio State University, Columbus, OH, Piedstat Solutions, Greenville, NC

Research Funding

Pharmaceutical/Biotech Company
Genentech

Background: AML is a disease of older adults, with median age of 68 years at presentation. NCCN guidelines suggest comprehensive geriatric assessments (GA) be included in clinical practice to guide treatment decisions. Utility of GA in older AML patients in a real-world environment is not yet established. We tested the feasibility of using a modified GA (mGA), administered by patient self-report on a touchscreen computer, real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making. Methods: Sixty-two patients were recruited from three sites to complete a tablet-based mGA screening at a treatment decision-making time point. The mGA consists of the Frailty Index (FI) that includes four domains: age, activities of daily living, instrumental ADLs, and comorbidities. Falls within the past 6 months and patient reported health interference with function are also assessed. Results are displayed for the clinician to inform the treatment discussion. Results: Participants were mean age 73 years (range 61-88), 63% male, and 90% white. Frailty Index result was 32% fit, 40% intermediate, and 28% frail. Providers were asked the fit/frailty status prior to seeing the results of the mGA. Of 53 provider responses, there was 57% (n=30) provider concordance with the mGA result; 9% (n=5) said fit when mGA said intermediate and 17% (n=9) said intermediate when mGA said frail. When asked their goals of care, nearly all (n=60, 97%) patients agreed with the statement “my cancer is curable”, yet 30% (n=19) disagreed the treatment goal was to get rid of all the cancer. Nearly half (n=30) indicated they want to make treatment decisions together with the provider rather than provider or patient making decision alone. 73% (45/62) of patients were satisfied with the ease of using the survey and took an average 16.3 minutes to complete. Patient self-reported presence/severity of eight symptoms at baseline (see Table). Conclusions: A simple electronic tool may provide valuable insight into patient understanding of disease to better tailor patient-provider discussion and treatment decision-making. Providers overestimated fitness 26% of the time. Final results will be presented to include the outcome at 3 months by Frailty Index.

Scale 1-10NLower QuartileMedianUpper Quartile
Tiredness564.006.008.50
Drowsiness463.505.006.00
Shortness of breath355.507.008.50
Lack of appetite322.004.005.50
Anxiety312.504.505.50
Pain312.003.005.00
Depression192.503.005.50
Nausea151.002.005.50

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Publication Only

Session Title

Publication Only: Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Geriatric Models of Care

Citation

J Clin Oncol 38: 2020 (suppl; abstr e24030)

DOI

10.1200/JCO.2020.38.15_suppl.e24030

Abstract #

e24030

Abstract Disclosures

Similar Abstracts

First Author: Andrew Gahagan

First Author: Maria Regina Girones Sarrio

First Author: Davide Bimbatti